Bone sarcomas are rare heterogeneous tumors that affect patients of all ages including children, adolescent young adults, and older adults. They include many aggressive subtypes and patient groups ...
SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare ...
The last time I spoke about Inhibrx Biosciences, Inc. (INBX) it was in a Seeking Alpha article entitled "Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing." With respect to ...
13d
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans
Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI produced a 20% objective response rate, 5.5-month median progression-free survival ...
Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo Key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results